



Janssen in Neuroscience

Gisella Dante

Managing Director Janssen Greece, Poland and Romania

Sep 10th , 2020

Melinda, *Tree of Life*
Melinda's artwork reflects
her journey living with HIV.



PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*

Mental health issues affect all of us across society



Patients tell us that their lives can be devastated by their condition

*"Mental health, much like the colour of your skin, **doesn't define you**"*

*"My depression is almost like a **living thing**, it wants to survive and thrive"*

*"It was obvious to everyone **except me** how sick I was"*

Globally, 1 in 4 people are affected by mental disorders at some point in their lives¹

Mental health disorders are among the leading causes of ill health worldwide,² and the burden of mental disorders continues to grow³

People with mental health disorders experience disproportionately higher rates of disability and mortality⁴



1. World Health Organization. World Health Report. Available at http://www.who.int/whr/2001/media_centre/press_release/en/ (last accessed April 2019).

2. Global Burden of Disease Study 2013 Collaborators. *Lancet* 2015;386(9995):743–800.

3. World Health Organization. Mental Disorders Fact Sheet 2018. Available at <http://www.who.int/en/news-room/fact-sheets/detail/mental-disorders> (last accessed April 2019).

4. World Health Organization. Mental Health Action Plan 2013–2020. Available at https://www.who.int/mental_health/action_plan_2013/en/ (last accessed April 2019).

Addressing **unmet need** in depression



We are using emerging science to develop novel compounds and address unmet medical needs for severe mood disorders



40 million
people across
EU are
affected with
depression¹


Depression is the leading cause of disability and disease burden worldwide according to the WHO,² with a high unmet need

Mental disorders are associated with **more than 90%** of all cases of suicide³

It is our mission to reduce the burden, disability and devastation caused by mental health disorders and transform individual lives

1. World Health Organization. Depression and Other Common Mental Disorders 2017. Available at http://www.who.int/mental_health/management/depression/prevalence_global_health_estimates/en/ (last accessed April 2019).
2. World Health Organization. Depression Fact Sheet 2018. Available at <http://www.who.int/news-room/fact-sheets/detail/depression> (last accessed April 2019).
3. World Health Organization. Background of SUPRE. Available at http://www.who.int/mental_health/prevention/suicide/background/en/ (last accessed April 2019).

We seek strategic **partnerships** and **collaborations** to drive innovation



We believe that collaboration with external innovators is essential to drive the types of discoveries that will bring forth the treatments and preventive strategies of tomorrow for neurodegenerative diseases.

Husseini Manji

MD, Global Head, Neuroscience, Janssen Research & Development

Every year the Johnson & Johnson Family of companies enters into **more than 200 collaborations** with external organisations to conduct research, harness new technologies, pursue scientific innovations, improve education and enhance the way we work

The **Janssen Innovation Centre** supports improved innovation in everything we do

Our four Innovation Centre hubs bring together world expert partners in science & technology to deliver integrated healthcare solutions which **put patients at the centre of healthcare provision**

We actively pursue licensing, acquisition, academic partnerships and public-private partnership opportunities to **advance knowledge, education and innovation**

Proven dedication, with a heritage spanning over 60 years



Our journey began in 1958 with Dr Paul Janssen's discovery of a pioneering schizophrenia therapy which **transformed the lives** of those living with this condition



This discovery made the shift from institutionalisation a reality for many patients with schizophrenia



Today, through our continued work, we have a deep understanding of the functions of the brain and have developed more than **20 medications and innovations** for the central nervous system




Two of our psychiatric medicines are recognised by the World Health Organization as **essential medicines**¹

We have
developed
over 20
innovations

1. World Health Organization. Model List of Essential Medicines 2017. Available at <http://www.who.int/medicines/publications/essentialmedicines/en/> (last accessed April 2019).

In the words of our founding father



“

*There is so much more to be done,
the patients are waiting.*

”

Dr Paul Janssen

Today, we have
40,000 employees
globally and
14,000 working
across EMEA



Mission

To reduce the burden,
disability and devastation
caused by mental health
disorders and transform
individual lives

Our Promise

**At Janssen, we're
creating a future
where disease is a
thing of the past**

